[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561993":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":17,"responsibleParty":34,"collaborators":37,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Luigi Di Filippo, medical doctor","CONTACT","+39 0226435062","difilippo.luigi@hsr.it",{"name":15,"role":11,"phone":12,"phoneExt":7,"email":16},"Gabriela Felipe, clinical research nurse","felipe.gabriela@hsr.it",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Andrea Giustina","RECRUITING","Milan","20132","Italy",{"type":25,"coordinates":26},"Point",[27,28],9.18951,45.46427,{"lat":28,"lon":27},[31],{"name":32,"role":11,"phone":33,"phoneExt":7,"email":16},"Gabriela Felipe, nurse","0226435062",{"type":35,"investigatorFullName":19,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Professor of Endocrinology",[38,40,42],{"name":39,"class":6},"University of Turin, Italy",{"name":41,"class":6},"University of Padova",{"name":43,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","100561993",false,"NCT06597383","The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly","The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly ( RAPSODIA )","RAPSODIA","Inclusion Criteria:\n\n* Adult men and women (age ≥ 18 years) affected by acromegaly, including those of childbearing age\n* Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 μg\u002FL and IGF-1 \\>1.3×ULN)\n* Second line medical treatment (Pasireotide; Pegvisomant only; combination Pegvisomant + 1st generation SSA) after use of first-line medical treatment\n* At least 12 months of follow up during 2nd line therapy\n* Signature of the informed consent to the study\n\nExclusion Criteria:\n\n* age ≤18 years\n* Pregnant and\u002For breastfeeding women\n* Patients unable to understand and sign the Informed Consent","ALL","18 Years",{"count":54,"type":55},100,"ESTIMATED","OBSERVATIONAL","This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.",[59],"Acromegaly",[61,62,63],"somatostatin analogues","pasireotide","pegvisomant","2024-09-11",{"date":66,"type":67},"2024-09-19","ACTUAL",{"date":69,"type":67},"2023-11-24",{"date":71,"type":55},"2024-11",{"name":5,"class":6},1]